Subtype
Malignant Oral Cavity Neoplasm
CI-CAN-00003197Explore in graph →
111 active trials2 evidence items
- NCIt
- C9314
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003197Explore in graph →
Clinical trials
379 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (45)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05452408 | Antitumor-B KAC PK Study | withdrawn | Phase 1 | 0 | Medical College of WisconsinOTHER | 1 | Mar 18, 2025 | clinicaltrials |
| NCT02827838 | Durvalumab Before Surgery in Treating Patients With Oral Cavity or Oropharynx Cancer | terminated | Early Phase 1 | 17 | Wake Forest University Health SciencesOTHER | 1 | Mar 17, 2025 | clinicaltrials |
| NCT06861036 |
| Heterogeneity of Oral Squamous Cell Carcinoma Analysis by Single Cell RNA Sequencing(HOASIS) |
| not yet recruiting |
| N/A |
| 50 |
| Centre Leon BerardOTHER |
| 1 |
| Mar 6, 2025 |
| clinicaltrials |
| NCT03721757 | CA209-891: Neoadjuvant and Adjuvant Nivolumab as Immune Checkpoint Inhibition in Oral Cavity Cancer(NICO) | completed | Phase 2 | 21 | The Clatterbridge Cancer Centre NHS Foundation TrustOTHER | 1 | Feb 25, 2025 | clinicaltrials |
| NCT06728631 | Candonilimab and ATRA Acid for Prevention of Oral Cancer Recurrence in Patients With OPL | active not recruiting | Phase 2 | 22 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityOTHER | 1 | Feb 24, 2025 | clinicaltrials |
| NCT04588038 | NT-I7 for the Treatment of Recurrent Squamous Cell Carcinoma of Head and Neck Undergoing Surgery | terminated | Phase 1 | 4 | Hyunseok Kang, MDOTHER | 1 | Feb 14, 2025 | clinicaltrials |
| NCT04162873 | Celecoxib Through Surgery and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer | terminated | Phase 2 | 13 | University of UtahOTHER | 1 | Feb 12, 2025 | clinicaltrials |
| NCT06806683 | Predictive Tools in Head and Neck Cancer Patients Undergoing Radiotherapy(ITHACA) | active not recruiting | — | 915 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Feb 4, 2025 | clinicaltrials |
| NCT05451303 | Detection of Oral and Throat Cancers Using OralViome Cancer Testing System | recruiting | — | 475 | ViomeINDUSTRY | 1 | Jan 29, 2025 | clinicaltrials |
| NCT06174428 | Validity of Viome's Oral/throat Cancer Test | recruiting | — | 1,000 | ViomeINDUSTRY | 1 | Jan 29, 2025 | clinicaltrials |
| NCT04883645 | Neoadjuvant Imiquimod Immunotherapy for Oral Cancer | completed | Early Phase 1 | 16 | Medical University of South CarolinaOTHER | 1 | Jan 28, 2025 | clinicaltrials |
| NCT03459729 | Pharmacokinetic (PK) Analysis of Antitumor B in Patients With Oral Cancer | completed | Early Phase 1 | 6 | Medical College of WisconsinOTHER | 1 | Jan 16, 2025 | clinicaltrials |
| NCT04649476 | Neoadjuvant PD-1 Blockade in Resectable Oral Squamous Cell Carcinoma(NEOPBOSCC) | completed | Phase 2 | 68 | Hospital of Stomatology, Wuhan UniversityOTHER | 1 | Jan 10, 2025 | clinicaltrials |
| NCT04028479 | The Registry of Oncology Outcomes Associated With Testing and Treatment(ROOT) | completed | — | 167 | Taproot HealthINDUSTRY | 1 | Dec 18, 2024 | clinicaltrials |
| NCT06728618 | Preoperative Tislelizumab -Cetuximab - Chemotherapy Followed by Salvage Surgery and Adjuvant Tislelizumab -Cetuximab for Resectable, Locally Recurrent Oral and Oropharyngeal Squamous Cell Carcinoma(OSCC) | not yet recruiting | Phase 2 | 28 | Shanghai Zhongshan HospitalOTHER | 1 | Dec 11, 2024 | clinicaltrials |
| NCT06726512 | Quantitative Margin Assessment Using High-resolution Positron Emission Tomography - Computed Tomograhy(qMAP) | not yet recruiting | N/A | 30 | University Medical Center GroningenOTHER | 1 | Dec 10, 2024 | clinicaltrials |
| NCT04985357 | Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs | withdrawn | — | 0 | Travera IncINDUSTRY | 0 | Nov 25, 2024 | clinicaltrials |
| NCT06690918 | Risk Factors Contributing to Oral Cancer in Patients at Dr. Hasan Sadikin General Hospital Bandung | completed | — | 107 | Universitas PadjadjaranOTHER | 1 | Nov 15, 2024 | clinicaltrials |
| NCT06380686 | Head and Neck Carcinoma Clinical Research Platform for Molecular and Blood-based Biomarkers, Treatment and Outcome(HEAT) | recruiting | — | 120 | AIO-Studien-gGmbHOTHER | 1 | Nov 13, 2024 | clinicaltrials |
| NCT05950737 | Sentinel Node Biopsy in Early Oral Cancers a Tertiary Cancer Centre Experience | completed | N/A | 115 | Tata Memorial HospitalOTHER_GOV | 1 | Oct 30, 2024 | clinicaltrials |
| NCT04870840 | Image-guided Proton Therapy for the Treatment of Locally Advanced Unresectable Head and Neck Cancer | completed | Phase 1 | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 29, 2024 | clinicaltrials |
| NCT06662929 | Arabic PRO Measures for Head and Neck Cancer Radiotherapy.(PROMs) | recruiting | — | 125 | King Saud UniversityOTHER | 1 | Oct 29, 2024 | clinicaltrials |
| NCT05369234 | Effects of Oral Aloe Vera Juice on Chemotherapy and Radiation-induced Oral Mucositis and Esophagitis | completed | Phase 3 | 100 | Covenant Health Cancer CenterOTHER | 1 | Oct 10, 2024 | clinicaltrials |
| NCT05696314 | Surgeon-performed Outpatient Transoral and Transcervical Ultrasound of the Oropharynx(SPOT-US) | completed | N/A | 201 | Rigshospitalet, DenmarkOTHER | 1 | Oct 3, 2024 | clinicaltrials |
| NCT06031337 | Salivary Expression of SOX7 in Oral Squamous Cell Carcinoma: Diagnostic Accuracy Study | completed | — | 46 | Fayoum UniversityOTHER | 1 | Sep 27, 2024 | clinicaltrials |
| NCT06609070 | CHG0521 Oral Coating in Patients with Solid Tissue Tumor/Recurrent/Metastatic TSCC | not yet recruiting | N/A | 30 | Guangzhou University of Traditional Chinese MedicineOTHER | 0 | Sep 23, 2024 | clinicaltrials |
| NCT03028766 | WEE1 Inhibitor with Cisplatin and Radiotherapy: a Trial in Head and Neck Cancer(WISTERIA) | completed | Phase 1 | 9 | University of BirminghamOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT04718415 | Neoadjuvant Sintilimab in Combination With Carboplatin and Nab-paclitaxel in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma(OOC-001) | active not recruiting | Phase 2 | 51 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06599801 | Clinical Outcomes of Thoracodorsal Artery Flap in Oral and Maxillofacial Reconstruction | not yet recruiting | — | 217 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06425146 | Tobacco, Alcohol and Cancerization of the Oral Mucosa (TACO)(TACO) | unknown | N/A | 30 | Centre Leon BerardOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT05719779 | Tolerance and Benefits of Mandibular Advanced Device for Snoring and Sleep Apnea in Oropharyngeal Cancer.(Ronco-Onco) | unknown | N/A | 35 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | Aug 15, 2024 | clinicaltrials |
| NCT03181035 | Correlation of FAZA PET Hypoxia Imaging To 3D Histology in Oral Tongue Cancer(FAITH) | suspended | Phase 1 / Phase 2 | 10 | Sunnybrook Health Sciences CentreOTHER | 1 | Aug 12, 2024 | clinicaltrials |
| NCT01847326 | Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin Followed By Chemoradiation in Treating Patients With Recurrent Head and Neck Cancer | completed | Phase 1 | 48 | University of ChicagoOTHER | 1 | Jul 31, 2024 | clinicaltrials |
| NCT06084845 | Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carboplatin for Patients With Head and Neck Cancer | withdrawn | Phase 2 | 0 | ECOG-ACRIN Cancer Research GroupNETWORK | 0 | Jul 25, 2024 | clinicaltrials |
| NCT01064479 | Combination Chemotherapy With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck | completed | Phase 2 | 123 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT03784066 | Durvalumab With or Without Tremelimumab in Resectable Locally Advanced Squamous Cell Carcinoma of the Oral Cavity(DUTRELASCO) | unknown | Phase 1 / Phase 2 | 21 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT04541355 | Sodium Thiosulfate in Preventing Ototoxicity for Squamous Cell Cancer Patients Undergoing Chemoradiation With Cisplatin | completed | Phase 2 | 16 | Hyunseok Kang, MDOTHER | 1 | Jun 28, 2024 | clinicaltrials |
| NCT02923258 | Postoperative CCRT With Docetaxel vs Cisplatin in High Risk Oral Cavity Cancer | completed | Phase 2 / Phase 3 | 224 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityOTHER | 1 | Jun 20, 2024 | clinicaltrials |
| NCT06438939 | NBI for Early Diagnosis of OPMD/OSCC(NBI_Oral) | not yet recruiting | N/A | 480 | Cardarelli HospitalOTHER | 1 | Jun 3, 2024 | clinicaltrials |
| NCT06407570 | Dysphagia and Quality of Life in Patients With Oral Squamous Cell Carcinoma Before and After Treatment | not yet recruiting | — | 100 | University of AarhusOTHER | 1 | May 9, 2024 | clinicaltrials |
| NCT05798793 | Neoadjuvant Anti-PD-1 Immunotherapy With Chemotherapy in Resectable Locally Advanced Oral Squamous Cell Carcinoma(NEOPCOSCC) | recruiting | Phase 3 | 309 | Hospital of Stomatology, Wuhan UniversityOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT05098119 | Neoadjuvant Sintilimab Combined With Reduction of Cycles of Chemotherapy in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma (OOC-002) | recruiting | Phase 2 | 43 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Mar 26, 2024 | clinicaltrials |
| NCT03650699 | Biofeedback Rehabilitation to Improve Speaking and Eating in Public(Biofeedback) | completed | N/A | 34 | University Health Network, TorontoOTHER | 1 | Mar 20, 2024 | clinicaltrials |
| NCT02609386 | IRX-2 Regimen in Patients With Newly Diagnosed Stage II, III, or IVA Squamous Cell Carcinoma of the Oral Cavity(INSPIRE) | completed | Phase 2 | 105 | Brooklyn ImmunoTherapeutics, LLCINDUSTRY | 4 | Jan 30, 2024 | clinicaltrials |
| NCT05056064 | Efficacy of Swallowing Function After Early Postoperative Oral Exercise Among Patient With Oral Cavity Cancer Underwent Flap Reconstruction | completed | N/A | 90 | Department of Medical Services Ministry of Public Health of ThailandOTHER_GOV | 1 | Jan 25, 2024 | clinicaltrials |
| NCT04892875 | A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers(PANTHEoN) | withdrawn | Phase 1 | 0 | Jennifer ChoeOTHER | 0 | Nov 30, 2023 | clinicaltrials |
| NCT05069857 | Neoadjuvant Personalized Anti-PD-1 and Anti-VEGFR Therapy in OSCC Patients | recruiting | Phase 2 | 46 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT05125055 | Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC | recruiting | Phase 2 / Phase 3 | 80 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT05455632 | Postoperative Radiotherapy for Oral Squamous Cell Carcinoma After Neoadjuvant Therapy and Surgery | completed | — | 192 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Nov 22, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Mar 18, 2025source: clinicaltrials